Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.

[1]  R. C. Layton,et al.  Enhanced Immunogenicity, Mortality Protection, and Reduced Viral Brain Invasion by Alum Adjuvant with an H5N1 Split-Virion Vaccine in the Ferret , 2011, PloS one.

[2]  N. Petrovsky,et al.  Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers. , 2011, Glycobiology.

[3]  Shinji Watanabe,et al.  Subclinical Brain Injury Caused by H5N1 Influenza Virus Infection , 2011, Journal of Virology.

[4]  N. Petrovsky,et al.  Induction of mucosal and systemic antibody and T-cell responses following prime–boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations , 2011, The Journal of general virology.

[5]  C. Feare,et al.  Persistence of Highly Pathogenic Avian Influenza Viruses in Natural Ecosystems , 2010, Emerging infectious diseases.

[6]  N. Petrovsky,et al.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses , 2010, The Journal of general virology.

[7]  Alan S. Perelson,et al.  Quantifying the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus , 2010, Journal of Virology.

[8]  W. Keitel,et al.  Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. , 2010, Vaccine.

[9]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[10]  W. Keitel,et al.  Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. , 2009, Vaccine.

[11]  R. Webster,et al.  Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. , 2009, Vaccine.

[12]  I. Barr,et al.  Evaluation of Vaccines for H5N1 Influenza Virus in Ferrets Reveals the Potential for Protective Single-Shot Immunization , 2009, Journal of Virology.

[13]  R. C. Layton,et al.  Ferret model of avian influenza demonstrates dose and strain dependant pathology and viral load in brain , 2009 .

[14]  W. Keitel,et al.  Adjuvants for pandemic influenza vaccines. , 2009, Current topics in microbiology and immunology.

[15]  R. Tripp,et al.  Animal models for evaluation of influenza vaccines. , 2009, Current topics in microbiology and immunology.

[16]  T. Tumpey,et al.  Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. , 2009, Advances in virus research.

[17]  T. Chotpitayasunondh,et al.  Safety, Humoral and Cell Mediated Immune Responses to Two Formulations of an Inactivated, Split-Virion Influenza A/H5N1 Vaccine in Children , 2008, PloS one.

[18]  J. McVernon,et al.  Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. , 2008, Vaccine.

[19]  B. Palache.  New vaccine approaches for seasonal and pandemic influenza. , 2008, Vaccine.

[20]  W. Keitel,et al.  Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. , 2008, The Journal of infectious diseases.

[21]  M. Saville,et al.  Improving seasonal and pandemic influenza vaccines , 2008, Influenza and other respiratory viruses.

[22]  G. Kayali,et al.  Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[23]  R. Tripp,et al.  Recombinant vaccines for influenza virus. , 2008, Current opinion in investigational drugs.

[24]  D. Bernstein,et al.  Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. , 2008, The Journal of infectious diseases.

[25]  J. Treanor,et al.  Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. , 2008, The Journal of infectious diseases.

[26]  N. Petrovsky.  Freeing vaccine adjuvants from dangerous immunological dogma , 2008, Expert review of vaccines.

[27]  A. Osterhaus,et al.  Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine , 2008, PloS one.

[28]  A. Osterhaus,et al.  Vaccination of Macaques with Adjuvanted Formalin-Inactivated Influenza A Virus (H5N1) Vaccines: Protection against H5N1 Challenge without Disease Enhancement , 2007, Journal of Virology.

[29]  D. Krewski,et al.  Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide , 2007, Journal of toxicology and environmental health. Part B, Critical reviews.

[30]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[31]  Steven Riley,et al.  Optimizing the Dose of Pre-Pandemic Influenza Vaccines to Reduce the Infection Attack Rate , 2007, PLoS medicine.

[32]  K. Subbarao,et al.  Scientific barriers to developing vaccines against avian influenza viruses , 2007, Nature Reviews Immunology.

[33]  J. Katz,et al.  Influenza: Propagation, Quantification, and Storage , 2006, Current protocols in microbiology.

[34]  R. Webster,et al.  Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. , 2006, The Journal of infectious diseases.

[35]  N. Cox,et al.  Lack of transmission of H5N1 avian–human reassortant influenza viruses in a ferret model , 2006, Proceedings of the National Academy of Sciences.

[36]  A. Hampson.  Ferrets and the challenges of H5N1 vaccine formulation. , 2006, The Journal of infectious diseases.

[37]  R. Webster,et al.  Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. , 2006, The Journal of infectious diseases.

[38]  M. Zambon,et al.  Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.

[39]  N. Petrovsky.  Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. , 2006, Vaccine.

[40]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[41]  M. Kieny,et al.  Development and evaluation of influenza pandemic vaccines , 2006, The Lancet Infectious Diseases.

[42]  R. Webster,et al.  Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Diego G. Silva,et al.  Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses , 2004, Immunology and cell biology.

[44]  John A. Maher,et al.  The Ferret: An Animal Model to Study Influenza Virus , 2004, Lab Animal.

[45]  R. Webster,et al.  Protection and compensation in the influenza virus-specific CD8+ T cell response , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[47]  W. Gerhard.  The role of the antibody response in influenza virus infection. , 2001, Current topics in microbiology and immunology.

[48]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[49]  P. Cooper,et al.  The adjuvanticity of gamma inulin , 1988, Immunology and cell biology.

[50]  A. Kendal,et al.  Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection , 1988, Journal of clinical microbiology.